Adagene Net Income Per Share Over Time
| ADAG Stock | USD 2.40 0.15 6.67% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Adagene Performance and Adagene Correlation. Adagene |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adagene. If investors know Adagene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adagene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.73) | Revenue Per Share 0.019 | Quarterly Revenue Growth (0.85) | Return On Assets (0.20) | Return On Equity (0.46) |
The market value of Adagene is measured differently than its book value, which is the value of Adagene that is recorded on the company's balance sheet. Investors also form their own opinion of Adagene's value that differs from its market value or its book value, called intrinsic value, which is Adagene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adagene's market value can be influenced by many factors that don't directly affect Adagene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Adagene's value and its price as these two are different measures arrived at by different means. Investors typically determine if Adagene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adagene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Net Income Per Share Analysis
Compare Adagene and related stocks such as Aerovate Therapeutics, Acrivon Therapeutics,, and Rezolute Net Income Per Share Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AVTE | (0.1364) | (0.1364) | (0.1364) | (0.1364) | (0.1364) | (0.1364) | (0.1364) | (0.1364) | (0.1364) | (0.1364) | (0.3703) | (0.9407) | (2.1049) | (2.8681) | (2.72) |
| ACRV | (0.2544) | (0.2544) | (0.2544) | (0.2544) | (0.2544) | (0.2544) | (0.2544) | (0.2544) | (0.2544) | (0.2544) | (0.2544) | (0.7787) | (1.3538) | (2.7352) | (2.87) |
| RZLT | (0.6372) | (0.6372) | (54.2139) | (51.8424) | (27.1176) | (30.1446) | (24.5505) | (26.8276) | (17.1128) | (3.5356) | (2.7737) | (2.1312) | (1.0117) | (0.91) | (0.96) |
| ANTX | (0.3007) | (0.3007) | (0.3007) | (0.3007) | (0.3007) | (0.3007) | (0.3007) | (0.3007) | (0.3007) | (0.3007) | (0.7257) | (1.1459) | (2.1373) | (2.7429) | (2.88) |
| ANEB | (0.0074) | (0.0074) | (0.0074) | (0.0074) | (0.0074) | (0.0074) | (0.0074) | (0.0074) | (0.0074) | (0.0074) | (1.2964) | (0.2918) | (0.4679) | (0.54) | (0.56) |
| ANAB | (0.0948) | (0.0948) | (0.0948) | (0.0948) | 0.2495 | (0.3819) | (0.2345) | (1.5201) | (2.4989) | (3.5972) | (0.7296) | (2.085) | (4.5704) | (6.0771) | (5.77) |
| MLYS | (0.0877) | (0.0877) | (0.0877) | (0.0877) | (0.0877) | (0.0877) | (0.0877) | (0.0877) | (0.0877) | (0.0877) | (0.0877) | (0.4969) | (0.7294) | (1.9868) | (1.89) |
| ELYM | (0.1443) | (0.1443) | (0.1443) | (0.1443) | (0.1443) | (0.1443) | (0.1443) | (0.1443) | (0.1443) | (0.1443) | (0.4373) | (1.8098) | (1.7237) | (1.3013) | (1.37) |
| JANX | (0.1018) | (0.1018) | (0.1018) | (0.1018) | (0.1018) | (0.1018) | (0.1018) | (0.1018) | (0.1018) | (0.1018) | (0.1263) | (0.7894) | (1.3059) | (1.3244) | (1.39) |
| PMVP | (0.5615) | (0.5615) | (0.5615) | (0.5615) | (0.5615) | (0.5615) | (0.5615) | (0.5615) | (0.5615) | (0.5896) | (0.7691) | (1.2815) | (1.608) | (1.4362) | (1.51) |
| MOLN | 0.3665 | 0.3665 | 0.3665 | 0.3665 | (0.15) | (0.0076) | (0.9111) | (1.219) | (1.7496) | (1.6946) | (2.5105) | (2.0572) | 3.6296 | (1.8914) | (1.8) |
Adagene and related stocks such as Aerovate Therapeutics, Acrivon Therapeutics,, and Rezolute Net Income Per Share description
My Equities
My Current Equities and Potential Positions
| Adagene | ADAG |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | China |
| Exchange | NASDAQ Exchange |
USD 2.4
Additional Information and Resources on Investing in Adagene Stock
When determining whether Adagene is a strong investment it is important to analyze Adagene's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Adagene's future performance. For an informed investment choice regarding Adagene Stock, refer to the following important reports:Check out Adagene Performance and Adagene Correlation. For more detail on how to invest in Adagene Stock please use our How to Invest in Adagene guide.You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Adagene technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.